{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:44:18Z","timestamp":1789501458704,"version":"build-2803163510"},"reference-count":145,"publisher":"Journal of Biomedical Research","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2026]]},"DOI":"10.7555\/jbr.40.20260137","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:44:12Z","timestamp":1781955852000},"page":"1","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic CAR-T cell therapies: Overcoming clinical challenges and therapeutic potential against tumors"],"prefix":"10.7555","volume":"40","author":[{"given":"Raniya","family":"Khadiullina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigul","family":"Valiullina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvina","family":"Gilyazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Skibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabir","family":"Mukhametshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Bulatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4380","reference":[{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.1","doi-asserted-by":"publisher","unstructured":"Zhao Z, Chen Y, Francisco NM, et al. The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges[J]. <i>Acta Pharm Sin B<\/i>, 2018, 8(4): 539\u2013551.","DOI":"10.1016\/j.apsb.2018.03.001"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.2","doi-asserted-by":"publisher","unstructured":"Nair R, Neelapu SS. The promise of CAR T-cell therapy in aggressive B-cell lymphoma[J]. <i>Best Pract Res Clin Haematol<\/i>, 2018, 31(3): 293\u2013298.","DOI":"10.1016\/j.beha.2018.07.011"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.3","doi-asserted-by":"publisher","unstructured":"Hanssens H, Meeus F, De Veirman K, et al. The antigen-binding moiety in the driver\u2019s seat of CARs[J]. <i>Med Res Rev<\/i>, 2022, 42(1): 306\u2013342.","DOI":"10.1002\/med.21818"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.4","doi-asserted-by":"publisher","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains[J]. <i>Nat Rev Clin Oncol<\/i>, 2021, 18(11): 715\u2013727.","DOI":"10.1038\/s41571-021-00530-z"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.5","doi-asserted-by":"crossref","unstructured":"Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell non-Hodgkin\u2019s lymphomas[J]. <i>Am J Cancer Res<\/i>, 2016, 6(2): 403\u2013424.","DOI":"10.19080\/CTOIJ.2017.06.555682"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.6","doi-asserted-by":"publisher","unstructured":"Wang T, He T, Ma L, et al. Clinical outcomes of BCMA CAR-T cells in a multiple myeloma patient with central nervous system invasion[J]. <i>Front Oncol<\/i>, 2022, 12: 854448.","DOI":"10.3389\/fonc.2022.854448"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.7","doi-asserted-by":"publisher","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: What we know so far[J]. <i>Nat Rev Clin Oncol<\/i>, 2023, 20(6): 359\u2013371.","DOI":"10.1038\/s41571-023-00754-1"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.8","doi-asserted-by":"publisher","unstructured":"Sasu BJ, Lauron EJ, Schulz T, et al. Allogeneic CAR T cell therapy for cancer[J]. <i>Annu Rev Cancer Biol<\/i>, 2024, 8: 227\u2013243.","DOI":"10.1146\/annurev-cancerbio-062822-023316"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.9","doi-asserted-by":"publisher","unstructured":"Du B, Qin J, Lin B, et al. CAR-T therapy in solid tumors[J]. <i>Cancer Cell<\/i>, 2025, 43(4): 665\u2013679.","DOI":"10.1016\/j.ccell.2025.03.019"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.10","doi-asserted-by":"publisher","unstructured":"Zong J, Li YR. iPSC technology revolutionizes CAR-T cell therapy for cancer treatment[J]. <i>Bioengineering (Basel)<\/i>, 2025, 12(1): 60.","DOI":"10.3390\/bioengineering12010060"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.11","doi-asserted-by":"publisher","unstructured":"Chen S, van den Brink MRM. Allogeneic \u201coff-the-shelf\u201d CAR T cells: Challenges and advances[J]. <i>Best Pract Res Clin Haematol<\/i>, 2024, 37(3): 101566.","DOI":"10.1016\/j.beha.2024.101566"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.12","doi-asserted-by":"publisher","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: Key lessons to learn and unlearn[J]. <i>Nat Rev Clin Oncol<\/i>, 2024, 21(1): 47\u201366.","DOI":"10.1038\/s41571-023-00832-4"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.13","doi-asserted-by":"publisher","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019Connor RS, et al. Reducing <i>ex vivo<\/i> culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells[J]. <i>Cancer Immunol Res<\/i>, 2018, 6(9): 1100\u20131109.","DOI":"10.1158\/2326-6066.CIR-17-0405"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.14","doi-asserted-by":"publisher","unstructured":"Kourelis T, Bansal R, Berdeja J, et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: A multi-institution experience[J]. <i>Transplant Cell Ther<\/i>, 2023, 29(4): 255\u2013258.","DOI":"10.1016\/j.jtct.2023.01.012"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.15","doi-asserted-by":"publisher","unstructured":"Litvinova Y, Merkur S, Allin S, et al. Availability and financing of CAR-T cell therapies: A cross-country comparative analysis[J]. <i>Health Policy<\/i>, 2024, 149: 105153.","DOI":"10.1016\/j.healthpol.2024.105153"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.16","doi-asserted-by":"publisher","unstructured":"Depil S, Duchateau P, Grupp SA, et al. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: Development and challenges[J]. <i>Nat Rev Drug Discov<\/i>, 2020, 19(3): 185\u2013199.","DOI":"10.1038\/s41573-019-0051-2"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.17","unstructured":"Lin MY, Yoon H, Nguyen A, et al. Allogeneic CAR T cells derived from younger donor T cells have more desirable T cell phenotype and better in vitro functionality[C]\/\/Poster Presented at the 25th ASGCT Conference. 2022: 16\u201319. <b><\/b>"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.18","doi-asserted-by":"publisher","unstructured":"Geethakumari PR, Ramasamy DP, Dholaria B, et al. Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments[J]. <i>Curr Hematol Malig Rep<\/i>, 2021, 16(4): 345\u2013356.","DOI":"10.1007\/s11899-021-00635-3"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.19","doi-asserted-by":"publisher","unstructured":"Mansoori S, Noei A, Maali A, et al. Recent updates on allogeneic CAR-T cells in hematological malignancies[J]. <i>Cancer Cell Int<\/i>, 2024, 24(1): 304.","DOI":"10.1186\/s12935-024-03479-y"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.20","doi-asserted-by":"publisher","unstructured":"Ahmed N, Wesson W, Mushtaq MU, et al. \u201cWaitlist mortality\u201d is high for myeloma patients with limited access to BCMA therapy[J]. <i>Front Oncol<\/i>, 2023, 13: 1206715.","DOI":"10.3389\/fonc.2023.1206715"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.21","doi-asserted-by":"publisher","unstructured":"Lonez C, Breman E. Allogeneic CAR-T therapy technologies: Has the promise been met?[J]. <i>Cells<\/i>, 2024, 13(2): 146.","DOI":"10.3390\/cells13020146"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.22","doi-asserted-by":"publisher","unstructured":"Sung AD, Chao NJ. Concise review: Acute graft-versus-host disease: Immunobiology, prevention, and treatment[J]. <i>Stem Cells Transl Med<\/i>, 2013, 2(1): 25\u201332.","DOI":"10.5966\/sctm.2012-0115"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.23","doi-asserted-by":"publisher","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease\u2014biologic process, prevention, and therapy[J]. <i>N Engl J Med<\/i>, 2017, 377(22): 2167\u20132179.","DOI":"10.1056\/NEJMra1609337"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.24","doi-asserted-by":"publisher","unstructured":"Abdelhakim H, Abdel-Azim H, Saad A. Role of \u03b1\u03b2 T cell depletion in prevention of graft versus host disease[J]. <i>Biomedicines<\/i>, 2017, 5(3): 35.","DOI":"10.3390\/biomedicines5030035"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.25","doi-asserted-by":"publisher","unstructured":"Mo F, Mamonkin M, Brenner MK, et al. Taking T-cell oncotherapy off-the-shelf[J]. <i>Trends Immunol<\/i>, 2021, 42(3): 261\u2013272.","DOI":"10.1016\/j.it.2021.01.004"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.26","doi-asserted-by":"publisher","unstructured":"Qasim W. Genome-edited allogeneic donor \u201cuniversal\u201d chimeric antigen receptor T cells[J]. <i>Blood<\/i>, 2023, 141(8): 835\u2013845.","DOI":"10.1182\/blood.2022016204"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.27","doi-asserted-by":"publisher","unstructured":"Torikai H, Reik A, Liu P, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR[J]. <i>Blood<\/i>, 2012, 119(24): 5697\u20135705.","DOI":"10.1182\/blood-2012-01-405365"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.28","doi-asserted-by":"publisher","unstructured":"Cooper ML, Choi J, Staser K, et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies[J]. <i>Leukemia<\/i>, 2018, 32(9): 1970\u20131983.","DOI":"10.1038\/s41375-018-0065-5"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.29","doi-asserted-by":"publisher","unstructured":"Sommer C, Boldajipour B, Kuo TC, et al. Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma[J]. <i>Mol Ther<\/i>, 2019, 27(6): 1126\u20131138.","DOI":"10.1016\/j.ymthe.2019.04.001"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.30","doi-asserted-by":"publisher","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the <i>TRAC<\/i> locus with CRISPR\/Cas9 enhances tumour rejection[J]. <i>Nature<\/i>, 2017, 543(7643): 113\u2013117.","DOI":"10.1038\/nature21405"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.31","doi-asserted-by":"publisher","unstructured":"Moradi V, Khodabandehloo E, Alidadi M, et al. Progress and pitfalls of gene editing technology in CAR-T cell therapy: A state-of-the-art review[J]. <i>Front Oncol<\/i>, 2024, 14: 1388475.","DOI":"10.3389\/fonc.2024.1388475"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.32","doi-asserted-by":"publisher","unstructured":"Petri K, D\u2019Ippolito E, K\u00fcnkele A, et al. Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: Challenges and opportunities[J]. <i>Nat Rev Clin Oncol<\/i>, 2025, 22(12): 902\u2013923.","DOI":"10.1038\/s41571-025-01072-4"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.33","doi-asserted-by":"publisher","unstructured":"Neelapu SS, Nath R, Munoz J, et al. ALPHA study: ALLO-501 produced deep and durable responses in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma comparable to autologous CAR T[J]. <i>Blood<\/i>, 2021, 138(S1): 3878.","DOI":"10.1182\/blood-2021-146038"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.34","doi-asserted-by":"publisher","unstructured":"Benjamin R, Jain N, Maus MV, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): A phase 1, dose-escalation trial[J]. <i>Lancet Haematol<\/i>, 2022, 9(11): e833\u2013e843.","DOI":"10.1016\/S2352-3026(22)00245-9"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.35","doi-asserted-by":"publisher","unstructured":"Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results[J]. <i>Nat Med<\/i>, 2023, 29(2): 422\u2013429.","DOI":"10.1038\/s41591-022-02182-7"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.36","doi-asserted-by":"crossref","unstructured":"McGuirk JP, Tam CS, Kr\u00f6ger N, et al. CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): Results from the phase 1 dose escalation carbon study[J]. <i>Blood<\/i>, 2022, 140(S1): 10303\u201310306.","DOI":"10.1182\/blood-2022-166432"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.37","doi-asserted-by":"publisher","unstructured":"Ghobadi A, Aldoss I, Maude S, et al. P356: Phase 1\/2 dose-escalation study of anti-CD7 allogenic CAR-T cell in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (T-ALL\/LBL)[J]. <i>HemaSphere<\/i>, 2023, 7(S3): e1789302.","DOI":"10.1097\/01.hs9.0000968336.17893.02"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.38","doi-asserted-by":"crossref","unstructured":"Wang X, Wu X, Tan B, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis[J]. <i>Cell<\/i>, 2024, 187(18): 4890\u20134904. e9.","DOI":"10.1016\/j.cell.2024.06.027"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.39","doi-asserted-by":"publisher","unstructured":"Su J, Zeng Y, Song Z, et al. Genome-edited allogeneic CAR-T cells: The next generation of cancer immunotherapies[J]. <i>J Hematol Oncol<\/i>, 2025, 18(1): 90.","DOI":"10.1186\/s13045-025-01745-8"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.40","doi-asserted-by":"publisher","unstructured":"Wu Y, Kyle-Cezar F, Woolf RT, et al. An innate-like V\u03b41<sup>+<\/sup> \u03b3\u03b4 T cell compartment in the human breast is associated with remission in triple-negative breast cancer[J]. <i>Sci Transl Med<\/i>, 2019, 11(513): eaax9364.","DOI":"10.1126\/scitranslmed.aax9364"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.41","doi-asserted-by":"publisher","unstructured":"Zakeri N, Hall A, Swadling L, et al. Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma[J]. <i>Nat Commun<\/i>, 2022, 13(1): 1372.","DOI":"10.1038\/s41467-022-29012-1"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.42","doi-asserted-by":"publisher","unstructured":"Jhita N, Raikar SS. Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies[J]. <i>Explor Immunol<\/i>, 2022, 2(3): 334\u2013350.","DOI":"10.37349\/ei.2022.00054"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.43","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Stevens DA, Hamadani M, et al. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta1 (\u03b3\u03b4) T cells in adults with B-cell malignancies[J]. <i>Blood<\/i>, 2022, 140(S1): 4617\u20134619.","DOI":"10.1182\/blood-2022-157400"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.44","doi-asserted-by":"publisher","unstructured":"Xie G, Dong H, Liang Y, et al. CAR-NK cells: A promising cellular immunotherapy for cancer[J]. <i>eBioMedicine<\/i>, 2020, 59: 102975.","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.45","doi-asserted-by":"publisher","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization[J]. <i>Signal Transduct Target Ther<\/i>, 2024, 9(1): 302.","DOI":"10.1038\/s41392-024-02005-w"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.46","doi-asserted-by":"publisher","unstructured":"Shimasaki N, Fujisaki H, Cho D, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies[J]. <i>Cytotherapy<\/i>, 2012, 14(7): 830\u2013840.","DOI":"10.3109\/14653249.2012.671519"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.47","doi-asserted-by":"publisher","unstructured":"Shao R, Li Z, Xin H, et al. Biomarkers as targets for CAR-T\/NK cell therapy in AML[J]. <i>Biomark Res<\/i>, 2023, 11(1): 65.","DOI":"10.1186\/s40364-023-00501-9"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.48","doi-asserted-by":"publisher","unstructured":"Yang K, Zhao Y, Sun G, et al. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy[J]. <i>Front Immunol<\/i>, 2023, 13: 1081546.","DOI":"10.3389\/fimmu.2022.1081546"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.49","doi-asserted-by":"publisher","unstructured":"Matsuda JL, Mallevaey T, Scott-Browne J, et al. CD1d-restricted iNKT cells, the \u2018Swiss-Army knife\u2019 of the immune system[J]. <i>Curr Opin Immunol<\/i>, 2008, 20(3): 358\u2013368.","DOI":"10.1016\/j.coi.2008.03.018"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.50","doi-asserted-by":"publisher","unstructured":"Metelitsa LS. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans[J]. <i>Clin Immunol<\/i>, 2011, 140(2): 119\u2013129.","DOI":"10.1016\/j.clim.2010.10.005"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.51","doi-asserted-by":"publisher","unstructured":"Li YR, Zhou Y, Yu J, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method[J]. <i>Nat Biotechnol<\/i>, 2025, 43(3): 329\u2013344.","DOI":"10.1038\/s41587-024-02226-y"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.52","doi-asserted-by":"publisher","unstructured":"Li YR, Li Z, Zhu Y, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells[J]. <i>Med<\/i>, 2025, 6(10): 100804.","DOI":"10.1016\/j.medj.2025.100804"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.53","doi-asserted-by":"publisher","unstructured":"Li YR, Shen X, Zhu E, et al. Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell\u2013engineered mesothelin-redirected CAR-NKT cells[J]. <i>Proc Natl Acad Sci U S A<\/i>, 2025, 122(47): e2517786122.","DOI":"10.1073\/pnas.2517786122"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.54","doi-asserted-by":"publisher","unstructured":"Li YR, Fang Y, Niu S, et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies[J]. <i>Nat Commun<\/i>, 2025, 16(1): 1248.","DOI":"10.1038\/s41467-025-56270-6"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.55","doi-asserted-by":"publisher","unstructured":"Ramos CA, Courtney AN, Robinson SN, et al. Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: An interim analysis[J]. <i>Blood<\/i>, 2021, 138(S1): 2819.","DOI":"10.1182\/blood-2021-149712"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.56","doi-asserted-by":"publisher","unstructured":"Chaudhry MS, Karadimitris A. Role and regulation of CD1d in normal and pathological B cells[J]. <i>J Immunol<\/i>, 2014, 193(10): 4761\u20134768.","DOI":"10.4049\/jimmunol.1401805"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.57","doi-asserted-by":"publisher","unstructured":"Godfrey DI, Koay HF, McCluskey J, et al. The biology and functional importance of MAIT cells[J]. <i>Nat Immunol<\/i>, 2019, 20(9): 1110\u20131128.","DOI":"10.1038\/s41590-019-0444-8"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.58","doi-asserted-by":"publisher","unstructured":"Tourret M, Talvard-Balland N, Lambert M, et al. Human MAIT cells are devoid of alloreactive potential: Prompting their use as universal cells for adoptive immune therapy[J]. <i>J Immunother Cancer<\/i>, 2021, 9(10): e003123.","DOI":"10.1136\/jitc-2021-003123"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.59","doi-asserted-by":"publisher","unstructured":"Petley EV, Koay HF, Henderson MA, et al. MAIT cells regulate NK cell-mediated tumor immunity[J]. <i>Nat Commun<\/i>, 2021, 12(1): 4746.","DOI":"10.1038\/s41467-021-25009-4"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.60","doi-asserted-by":"publisher","unstructured":"Dogan M, Karhan E, Kozhaya L, et al. Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy[J]. <i>J Immunol<\/i>, 2022, 209(8): 1523\u20131531.","DOI":"10.4049\/jimmunol.2100856"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.61","doi-asserted-by":"publisher","unstructured":"Li YR, Zhu Y, Fang Y, et al. Emerging trends in clinical allogeneic CAR cell therapy[J]. <i>Med<\/i>, 2025, 6(8): 100677.","DOI":"10.1016\/j.medj.2025.100677"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.62","doi-asserted-by":"publisher","unstructured":"Balassa K, Rocha V. Anticancer cellular immunotherapies derived from umbilical cord blood[J]. <i>Expert Opin Biol Ther<\/i>, 2018, 18(2): 121\u2013134.","DOI":"10.1080\/14712598.2018.1402002"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.63","doi-asserted-by":"publisher","unstructured":"Kwoczek J, Riese SB, Tischer S, et al. Cord blood\u2013derived T cells allow the generation of a more na\u00efve tumor-reactive cytotoxic T-cell phenotype[J]. <i>Transfusion<\/i>, 2018, 58(1): 88\u201399.","DOI":"10.1111\/trf.14365"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.64","doi-asserted-by":"publisher","unstructured":"Liu D, Hong W, Qiu K, et al. Umbilical cord blood: A promising source for allogeneic CAR-T cells[J]. <i>Front Oncol<\/i>, 2022, 12: 944248.","DOI":"10.3389\/fonc.2022.944248"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.65","doi-asserted-by":"publisher","unstructured":"Van Caeneghem Y, De Munter S, Tieppo P, et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR\/CD3 receptor and exhibit specific antitumor capacities[J]. <i>Oncoimmunology<\/i>, 2017, 6(3): e1283460.","DOI":"10.1080\/2162402X.2017.1283460"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.66","doi-asserted-by":"publisher","unstructured":"Shi Y, Inoue H, Wu JC, et al. Induced pluripotent stem cell technology: A decade of progress[J]. <i>Nat Rev Drug Discov<\/i>, 2017, 16(2): 115\u2013130.","DOI":"10.1038\/nrd.2016.245"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.67","doi-asserted-by":"crossref","unstructured":"Jing R, Scarfo I, Najia MA, et al. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity[J]. <i>Cell Stem Cell<\/i>, 2022, 29(8): 1181\u20131196. e6.","DOI":"10.1016\/j.stem.2022.06.014"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.68","doi-asserted-by":"crossref","unstructured":"Wang Z, McWilliams-Koeppen HP, Reza H, et al. 3D-organoid culture supports differentiation of human CAR<sup>+<\/sup> iPSCs into highly functional CAR T cells[J]. <i>Cell Stem Cell<\/i>, 2022, 29(4): 515\u2013527. e8.","DOI":"10.1016\/j.stem.2022.02.009"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.69","doi-asserted-by":"publisher","unstructured":"Bot A, Rossi JM, Jiang Y, et al. Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy[J]. <i>Blood<\/i>, 2015, 126(23): 4426.","DOI":"10.1182\/blood.v126.23.4426.4426"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.70","doi-asserted-by":"publisher","unstructured":"Jo S, Das S, Williams A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing[J]. <i>Nat Commun<\/i>, 2022, 13(1): 3453.","DOI":"10.1038\/s41467-022-30896-2"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.71","doi-asserted-by":"publisher","unstructured":"Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition[J]. <i>Clin Cancer Res<\/i>, 2017, 23(9): 2255\u20132266.","DOI":"10.1158\/1078-0432.CCR-16-1300"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.72","doi-asserted-by":"publisher","unstructured":"Arce-Gomez B, Jones EA, Barnstable CJ, et al. The genetic control of HLA-A and B antigens in somatic cell hybrids: Requirement for \u03b2<sub>2<\/sub> microglobulin[J]. <i>Tissue Antigens<\/i>, 1978, 11(2): 96\u2013112.","DOI":"10.1111\/j.1399-0039.1978.tb01233.x"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.73","doi-asserted-by":"publisher","unstructured":"Lee J, Sheen JH, Lim O, et al. Abrogation of HLA surface expression using CRISPR\/Cas9 genome editing: A step toward universal T cell therapy[J]. <i>Sci Rep<\/i>, 2020, 10(1): 17753.","DOI":"10.1038\/s41598-020-74772-9"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.74","doi-asserted-by":"publisher","unstructured":"Bix M, Liao NS, Zijlstra M, et al. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice[J]. <i>Nature<\/i>, 1991, 349(6307): 329\u2013331.","DOI":"10.1038\/349329a0"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.75","doi-asserted-by":"publisher","unstructured":"Kagoya Y, Guo T, Yeung B, et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy[J]. <i>Cancer Immunol Res<\/i>, 2020, 8(7): 926\u2013936.","DOI":"10.1158\/2326-6066.CIR-18-0508"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.76","doi-asserted-by":"publisher","unstructured":"Deuse T, Hu X, Agbor-Enoh S, et al. The SIRP\u03b1\u2013CD47 immune checkpoint in NK cells[J]. <i>J Exp Med<\/i>, 2021, 218(3): e20200839.","DOI":"10.1084\/jem.20200839"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.77","doi-asserted-by":"publisher","unstructured":"Hammer Q, Perica K, Mbofung RM, et al. Combined genetic ablation of CD54 and CD58 in CAR engineered cytotoxic lymphocytes effectively averts allogeneic immune cell rejection[J]. <i>Blood<\/i>, 2022, 140(S1): 1165\u20131166.","DOI":"10.1182\/blood-2022-163086"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.78","doi-asserted-by":"publisher","unstructured":"Terrett JA, Kalaitzidis D, Dequeant ML, et al. Abstract ND02: CTX112 and CTX131: Next-generation CRISPR\/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors[J]. <i>Cancer Res<\/i>, 2023, 83(S7): ND02.","DOI":"10.1158\/1538-7445.am2023-nd02"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.79","doi-asserted-by":"publisher","unstructured":"Dholaria B, Shune LO, Kocoglu MH, et al. A phase 1 study of P-BCMA-ALLO1, a non-viral, allogeneic BCMA directed CAR-T in relapsed\/refractory multiple myeloma (RRMM): Results from optimized lymphodepletion cohort[J]. <i>Blood<\/i>, 2024, 144(S1): 4828.","DOI":"10.1182\/blood-2024-207459"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.80","doi-asserted-by":"publisher","unstructured":"Oh D, Vu P, Baranda JC, et al. 50P phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies[J]. <i>Immuno-Oncol Technol<\/i>, 2024, 24: 100861.","DOI":"10.1016\/j.iotech.2024.100861"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.81","doi-asserted-by":"publisher","unstructured":"Benjamin R, Graham C, Yallop D, et al. Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia[J]. <i>Blood<\/i>, 2018, 132(S1): 896.","DOI":"10.1182\/blood-2018-99-111356"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.82","doi-asserted-by":"crossref","unstructured":"Qasim W, Ciocarlie O, Adams S, et al. Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product in a first-in-human trial (PALL) in pediatric patients with CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia[J]. <i>Blood<\/i>, 2017, 130(S1): 1271.","DOI":"10.1182\/blood.V130.Suppl_1.887.887"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.83","doi-asserted-by":"publisher","unstructured":"Peng L, Sferruzza G, Yang L, et al. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors[J]. <i>Cell Mol Immunol<\/i>, 2024, 21(10): 1089\u20131108.","DOI":"10.1038\/s41423-024-01207-0"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.84","doi-asserted-by":"publisher","unstructured":"Das RK, Vernau L, Grupp SA, et al. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers[J]. <i>Cancer Discov<\/i>, 2019, 9(4): 492\u2013499.","DOI":"10.1158\/2159-8290.CD-18-1314"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.85","doi-asserted-by":"publisher","unstructured":"Chok R, Ramakrishna S. Allogeneic approach unlocks CAR T cell benefits in solid tumors[J]. <i>Nat Med<\/i>, 2025, 31(3): 733\u2013734.","DOI":"10.1038\/s41591-025-03510-3"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.86","doi-asserted-by":"publisher","unstructured":"Drougkas K, Karampinos K, Karavolias I, et al. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: A path moving forward or a dead end?[J]. <i>J Cancer Res Clin Oncol<\/i>, 2023, 149(6): 2709\u20132734.","DOI":"10.1007\/s00432-022-04547-4"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.87","doi-asserted-by":"publisher","unstructured":"Walsh Z, Ross S, Fry TJ. Multi-specific CAR targeting to prevent antigen escape[J]. <i>Curr Hematol Malig Rep<\/i>, 2019, 14(5): 451\u2013459.","DOI":"10.1007\/s11899-019-00537-5"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.88","doi-asserted-by":"publisher","unstructured":"Haist M, Stege H, Grabbe S, et al. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment[J]. <i>Cancers (Basel)<\/i>, 2021, 13(2): 210.","DOI":"10.3390\/cancers13020210"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.89","doi-asserted-by":"crossref","unstructured":"Mirlekar B. Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy[J]. <i>SAGE Open Med<\/i>, 2022, 10: 20503121211069012.","DOI":"10.1177\/20503121211069012"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.90","doi-asserted-by":"crossref","unstructured":"Kong X. Discovery of new immune checkpoints: Family grows up[M]\/\/Xu J. Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy. Singapore: Springer, 2020: 61\u201382.","DOI":"10.1007\/978-981-15-3266-5_4"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.91","doi-asserted-by":"publisher","unstructured":"Travis MA, Sheppard D. TGF-\u03b2 activation and function in immunity[J]. <i>Annu Rev Immunol<\/i>, 2014, 32(1): 51\u201382.","DOI":"10.1146\/annurev-immunol-032713-120257"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.92","doi-asserted-by":"publisher","unstructured":"Xing J, Zhang J, Wang J. The immune regulatory role of adenosine in the tumor microenvironment[J]. <i>Int J Mol Sci<\/i>, 2023, 24(19): 14928.","DOI":"10.3390\/ijms241914928"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.93","doi-asserted-by":"publisher","unstructured":"Newick K, O\u2019Brien S, Sun J, et al. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization[J]. <i>Cancer Immunol Res<\/i>, 2016, 4(6): 541\u2013551.","DOI":"10.1158\/2326-6066.CIR-15-0263"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.94","doi-asserted-by":"publisher","unstructured":"Wang Z, Li N, Feng K, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors[J]. <i>Cell Mol Immunol<\/i>, 2021, 18(9): 2188\u20132198.","DOI":"10.1038\/s41423-021-00749-x"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.95","doi-asserted-by":"publisher","unstructured":"Du H, Gong H, Wang Y, et al. High-affinity PD-1-CD28 switch receptor enhances sustained antitumor activity of CAR-T cells in both lymphoma and Ewing sarcoma[J]. <i>Blood<\/i>, 2025, 146(S1): 4102.","DOI":"10.1182\/blood-2025-4102"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.96","doi-asserted-by":"publisher","unstructured":"Tang N, Cheng C, Zhang X, et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors[J]. <i>JCI Insight<\/i>, 2020, 5(4): e133977.","DOI":"10.1172\/jci.insight.133977"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.97","doi-asserted-by":"publisher","unstructured":"Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication[J]. <i>Mol Ther<\/i>, 2018, 26(7): 1855\u20131866.","DOI":"10.1016\/j.ymthe.2018.05.003"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.98","doi-asserted-by":"publisher","unstructured":"Zhu S, Hu J, Lin J, et al. Co-expression of dominant-negative TGF-\u03b2 receptor 2 enhances the therapeutic efficacy of novel TREM1\/DAP12-BB-based CAR-T cells in solid tumours[J]. <i>Immunology<\/i>, 2025, 174(3): 310\u2013321.","DOI":"10.1111\/imm.13888"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.99","doi-asserted-by":"publisher","unstructured":"Zheng S, Che X, Zhang K, et al. Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal[J]. <i>Mol Ther<\/i>, 2025, 33(2): 688\u2013702.","DOI":"10.1016\/j.ymthe.2024.12.014"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.100","doi-asserted-by":"publisher","unstructured":"Giuffrida L, Sek K, Henderson MA, et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy[J]. <i>Nat Commun<\/i>, 2021, 12(1): 3236.","DOI":"10.1038\/s41467-021-23331-5"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.101","doi-asserted-by":"publisher","unstructured":"Hatfield SM. Engineering \u2018off-the-shelf\u2019 CAR-T cells resistant to biochemical and immunological barriers in the solid tumor microenvironment 2279[J]. <i>J Immunol<\/i>, 2025, 214(S1): vkaf283.214.","DOI":"10.1093\/jimmun\/vkaf283.214"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.102","doi-asserted-by":"publisher","unstructured":"Sun D, Shi X, Li S, et al. CAR-T cell therapy: A breakthrough in traditional cancer treatment strategies (review)[J]. <i>Mol Med Rep<\/i>, 2024, 29(3): 47.","DOI":"10.3892\/mmr.2024.13171"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.103","doi-asserted-by":"publisher","unstructured":"Mai D, Johnson O, Reff J, et al. Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells[J]. <i>Proc Natl Acad Sci U S A<\/i>, 2023, 120(12): e2218632120.","DOI":"10.1073\/pnas.2218632120"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.104","unstructured":"Hao J, Song Y, Li H, et al. Phase I open-label single-arm study to evaluate the safety, tolerability and preliminary efficacy of CHT102, an allogeneic mesothelin-targeted CAR-T Cell, in patients with advanced solid tumors (CHAPTER)[C]\/\/Molecular Therapy. Vol 33. Cell Press 50 Hampshire St, Floor 5, Cambridge, MA 02139 USA, 2025. <b><\/b>"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.105","doi-asserted-by":"publisher","unstructured":"Michaux A, Mau\u00ebn S, Breman E, et al. Clinical grade manufacture of CYAD-101, a NKG2D-based, first in class, non\u2013gene-edited allogeneic CAR T-cell therapy[J]. <i>J Immunother<\/i>, 2022, 45(3): 150\u2013161.","DOI":"10.1097\/CJI.0000000000000413"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.106","doi-asserted-by":"publisher","unstructured":"Prenen H, Dekervel J, Anguille S, et al. CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy[J]. <i>J Clin Oncol<\/i>, 2020, 38(S15): 3032.","DOI":"10.1200\/jco.2020.38.15_suppl.3032"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.107","doi-asserted-by":"crossref","unstructured":"Srour S, Kotecha R, Curti B, et al. Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)[J]. <i>Cancer Res<\/i>, 2023, 83(S8): CT011.","DOI":"10.1158\/1538-7445.AM2023-CT011"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.108","doi-asserted-by":"publisher","unstructured":"Srour SA, Chahoud J, Drakaki A, et al. ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study[J]. <i>J Clin Oncol<\/i>, 2025, 43(S16): 4508.","DOI":"10.1200\/jco.2025.43.16_suppl.4508"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.109","doi-asserted-by":"publisher","unstructured":"Ang WX, Ng YY, Xiao L, et al. Electroporation of NKG2D RNA CAR improves V\u03b39V\u03b42 T cell responses against human solid tumor xenografts[J]. <i>Mol Ther Oncolytics<\/i>, 2020, 17: 421\u2013430.","DOI":"10.1016\/j.omto.2020.04.013"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.110","doi-asserted-by":"publisher","unstructured":"Choo J, Tan WK, Luk L, et al. Abstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted \u03b3\u03b4 T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA trial)[J]. <i>Cancer Res<\/i>, 2024, 84(S7): CT160.","DOI":"10.1158\/1538-7445.am2024-ct160"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.111","doi-asserted-by":"publisher","unstructured":"Mukhametshin SA, Gilyazova EM, Davletshin DR, et al. Allogeneic NKG2D CAR-T cell therapy: A promising approach for treating solid tumors[J]. <i>Biomedicines<\/i>, 2025, 13(9): 2314.","DOI":"10.3390\/biomedicines13092314"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.112","doi-asserted-by":"publisher","unstructured":"Ma P, Wang S, Ma W, et al. Targeting cancer leptomeningeal metastasis with allogeneic chimeric antigen receptor \u03b3\u03b4 T-cell therapy[J]. <i>J Clin Oncol<\/i>, 2025, 43(S16): 2533.","DOI":"10.1200\/jco.2025.43.16_suppl.2533"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.113","doi-asserted-by":"publisher","unstructured":"Kirtane K, Park JC, Ulrickson M, et al. Logic-gated, allogeneic tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial[J]. <i>J Clin Oncol<\/i>, 2025, 43(S16): TPS2677.","DOI":"10.1200\/jco.2025.43.16_suppl.tps2677"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.114","doi-asserted-by":"publisher","unstructured":"Simeone D, Morelli MP, Hecht JR, et al. 639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN Logic-gated Tmod<sup>TM<\/sup> CAR T-cell therapy[J]. <i>J Immunother Cancer<\/i>, 2022, 10(S2): A670.","DOI":"10.1136\/jitc-2022-sitc2022.0639"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.115","doi-asserted-by":"crossref","unstructured":"Sasu BJ, Lauron EJ, Schulz T, et al. Allogeneic CAR T cell therapy for cancer[J]. <i>Annu Rev Cancer Biol<\/i>, 2024, 8: 227\u2013243. <b><\/b>","DOI":"10.1146\/annurev-cancerbio-062822-023316"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.116","unstructured":"US Food and Drug Administration. Considerations for the development of chimeric antigen receptor (CAR) T cell products[R]. Silver Spring: US Food and Drug Administration, 2024."},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.117","doi-asserted-by":"publisher","unstructured":"Sasu BJ, Opiteck GJ, Gopalakrishnan S, et al. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells[J]. <i>Mol Ther<\/i>, 2023, 31(3): 676\u2013685.","DOI":"10.1016\/j.ymthe.2022.12.004"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.118","doi-asserted-by":"publisher","unstructured":"Diorio C, Murray R, Naniong M, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL[J]. <i>Blood<\/i>, 2022, 140(6): 619\u2013629.","DOI":"10.1182\/blood.2022015825"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.119","doi-asserted-by":"publisher","unstructured":"Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: Results of two phase 1 studies[J]. <i>Lancet<\/i>, 2020, 396(10266): 1885\u20131894.","DOI":"10.1016\/S0140-6736(20)32334-5"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.120","doi-asserted-by":"publisher","unstructured":"Singh H, Huls H, Kebriaei P, et al. A new approach to gene therapy using <i>Sleeping Beauty<\/i> to genetically modify clinical-grade T cells to target CD19[J]. <i>Immunol Rev<\/i>, 2014, 257(1): 181\u2013190.","DOI":"10.1111\/imr.12137"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.121","unstructured":"US Food and Drug Administration. Considerations for the development of chimeric antigen receptor (CAR) T cell products[R]. Silver Spring: US Food and Drug Administration, 2024. <b><\/b>"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.122","doi-asserted-by":"publisher","unstructured":"Khaliulin M, Valiullina A, Petukhov A, et al. Breaking the shield of solid tumors: A combined approach for enhanced efficacy of CAR-T cells[J]. <i>Cancer Immunol Immunother<\/i>, 2024, 74(1): 3.","DOI":"10.1007\/s00262-024-03817-z"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.123","doi-asserted-by":"publisher","unstructured":"Al-Haideri M, Tondok SB, Safa SH, et al. CAR-T cell combination therapy: The next revolution in cancer treatment[J]. <i>Cancer Cell Int<\/i>, 2022, 22(1): 365.","DOI":"10.1186\/s12935-022-02778-6"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.124","doi-asserted-by":"publisher","unstructured":"Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy\u2014how far can we go?[J]. <i>Nat Clin Pract Oncol<\/i>, 2006, 3(12): 668\u2013681.","DOI":"10.1038\/ncponc0666"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.125","doi-asserted-by":"publisher","unstructured":"Hu B, Nastoupil LJ, Holmes H, et al. A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): Updated phase 1 results from the ANTLER trial[J]. <i>J Clin Oncol<\/i>, 2024, 42(S16): 7025.","DOI":"10.1200\/jco.2024.42.16_suppl.7025"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.126","doi-asserted-by":"publisher","unstructured":"Lv Y, Luo X, Xie Z, et al. Prospects and challenges of CAR-T cell therapy combined with ICIs[J]. <i>Front Oncol<\/i>, 2024, 14: 1368732.","DOI":"10.3389\/fonc.2024.1368732"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.127","doi-asserted-by":"publisher","unstructured":"Carneiro B, Garmezy B, Hamm JT, et al. Abstract CT275: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors[J]. <i>Cancer Res<\/i>, 2023, 83(S8): CT275.","DOI":"10.1158\/1538-7445.am2023-ct275"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.128","doi-asserted-by":"publisher","unstructured":"Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy[J]. <i>Signal Transduct Target Ther<\/i>, 2022, 7(1): 117.","DOI":"10.1038\/s41392-022-00951-x"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.129","doi-asserted-by":"publisher","unstructured":"Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors[J]. <i>Front Immunol<\/i>, 2024, 15: 1455163.","DOI":"10.3389\/fimmu.2024.1455163"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.130","doi-asserted-by":"publisher","unstructured":"Park A, Monroy I, Cook C, et al. 847 CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de novo CD19+ solid tumors[J]. <i>J Immunother Cancer<\/i>, 2022, 10(S2): A885.","DOI":"10.1136\/jitc-2022-sitc2022.0847"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.131","doi-asserted-by":"publisher","unstructured":"Maldini CR, Messana AC, Bendet PB, et al. Immunosuppressant therapy averts rejection of allogeneic <i>FKBP<\/i>1<i>A<\/i>-disrupted CAR-T cells[J]. <i>Mol Ther<\/i>, 2024, 32(10): 3485\u20133503.","DOI":"10.1016\/j.ymthe.2024.06.022"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.132","doi-asserted-by":"publisher","unstructured":"Li YR, Zhu Y, Halladay T, et al. In vivo CAR engineering for immunotherapy[J]. <i>Nat Rev Immunol<\/i>, 2025, 25(10): 725\u2013744.","DOI":"10.1038\/s41577-025-01174-1"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.133","doi-asserted-by":"publisher","unstructured":"Wilson B, Geetha KM. Lipid nanoparticles in the development of mRNA vaccines for COVID-19[J]. <i>J Drug Deliv Sci Technol<\/i>, 2022, 74: 103553.","DOI":"10.1016\/j.jddst.2022.103553"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.134","doi-asserted-by":"publisher","unstructured":"Billingsley MM, Gong N, Mukalel AJ, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism[J]. <i>Small<\/i>, 2024, 20(11): 2304378.","DOI":"10.1002\/smll.202304378"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.135","doi-asserted-by":"publisher","unstructured":"Zhou J, Sun L, Jia Y, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo[J]. <i>J Controlled Release<\/i>, 2022, 350: 298\u2013307.","DOI":"10.1016\/j.jconrel.2022.08.033"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.136","doi-asserted-by":"crossref","unstructured":"Li YR, Zhu Y, Halladay T, et al. In vivo CAR engineering for immunotherapy[J]. <i>Nat Rev Immunol<\/i>, 2025, 25(10): 725\u2013744. <b><\/b>","DOI":"10.1038\/s41577-025-01174-1"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.137","doi-asserted-by":"publisher","unstructured":"Smith TT, Stephan SB, Moffett HF, et al. <i>In situ<\/i> programming of leukaemia-specific T cells using synthetic DNA nanocarriers[J]. <i>Nat Nanotechnol<\/i>, 2017, 12(8): 813\u2013820.","DOI":"10.1038\/nnano.2017.57"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.138","doi-asserted-by":"publisher","unstructured":"Zieli\u0144ska A, Carreir\u00f3 F, Oliveira AM, et al. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology[J]. <i>Molecules<\/i>, 2020, 25(16): 3731.","DOI":"10.3390\/molecules25163731"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.139","doi-asserted-by":"publisher","unstructured":"Parayath NN, Stephan SB, Koehne AL, et al. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo[J]. <i>Nat Commun<\/i>, 2020, 11(1): 6080.","DOI":"10.1038\/s41467-020-19486-2"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.140","doi-asserted-by":"publisher","unstructured":"Short L, Holt RA, Cullis PR, et al. Direct <i>in vivo<\/i> CAR T cell engineering[J]. <i>Trends Pharmacol Sci<\/i>, 2024, 45(5): 406\u2013418.","DOI":"10.1016\/j.tips.2024.03.004"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.141","doi-asserted-by":"publisher","unstructured":"Agarwalla P, Ogunnaike EA, Ahn S, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells[J]. <i>Nat Biotechnol<\/i>, 2022, 40(8): 1250\u20131258.","DOI":"10.1038\/s41587-022-01245-x"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.142","doi-asserted-by":"publisher","unstructured":"Inamdar VV, Hao S, Stephan SB, et al. Biomaterial-based scaffolds for direct in situ programming of tumor-infiltrating T lymphocytes[J]. <i>J Controlled Release<\/i>, 2024, 370: 310\u2013317.","DOI":"10.1016\/j.jconrel.2024.04.040"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.143","doi-asserted-by":"publisher","unstructured":"Baek Y, Seo YR, Kim S, et al. From ex vivo to in vivo: Advances in lentiviral vector engineering for CAR-T therapy[J]. <i>Immune Netw<\/i>, 2026, 26(1): e13.","DOI":"10.4110\/in.2026.26.e13"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.144","doi-asserted-by":"publisher","unstructured":"Michels KR, Sheih A, Hernandez SA, et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering[J]. <i>J Immunother Cancer<\/i>, 2023, 11(3): e006292.","DOI":"10.1136\/jitc-2022-006292"},{"key":"10.7555\/JBR.40.20260137.swyxyjzzywb.145","doi-asserted-by":"publisher","unstructured":"Garcia J, Dehner C, Teoh J, et al. A phase 1, multicenter, open-label study of UB-VV111 in combination with Rapamycin in relapsed\/refractory CD19+ B-cell malignancies[J]. <i>Blood<\/i>, 2024, 144(S1): 1750.1.","DOI":"10.1182\/blood-2024-208461"}],"container-title":["Journal of Biomedical Research"],"original-title":[],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:02:36Z","timestamp":1782090156000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.40.20260137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":145,"alternative-id":["JBR-2026-0137"],"URL":"https:\/\/doi.org\/10.7555\/jbr.40.20260137","relation":{},"ISSN":["1674-8301","1674-8301"],"issn-type":[{"value":"1674-8301","type":"print"},{"value":"1674-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}